At the news
? BEARISHIMPACT 7/10 PRESS-RELEASE filed Jul 14, 2026 at 22:58 ET
Q32 Bio priced a $200 million underwritten public offering of common stock and pre-funded warrants, representing massive dilution of approximately 55% relative to its $363M market cap. The proceeds will fund working capital and clinical development of bempikibart for alopecia areata. The offering is expected to close July 16, 2026.
- $200 million gross proceeds from public offering of 6,027,399 shares at $18.25 and 4,931,506 pre-funded warrants at $18.2499
- Underwriters have a 30-day option to purchase up to an additional 1,643,835 shares at the offering price
- Proceeds to be used for working capital, including clinical development and commercialization of bempikibart
- Offering expected to close on or about July 16, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access